Abstract: Aminopyrimidine containing compounds that inhibit both Mer tyrosine kinase (MerTK) activity and Tyro3 kinase activity are disclosed herein. Additionally disclosed are methods of synthesis and use of the aminopyrimidine containing compounds as anti-cancer agents, immunostimulatory and immunomodulatory agents, anti-platelet agents, anti-infective agents, and as adjunctive agents.

Abstract: Compounds and compositions are provided that comprise selective b-glucuronidase inhibitors. The compounds and compositions can ameliorate the side effects of chemotherapeutic agents and can improve the efficacy of such agents, including irinotecan and non-steroidal anti-inflammatory drugs.

Abstract: A method of reducing carryover of liquids, such as reagent and/or samples, in analytical or immunoassay testing. The method includes providing an incubation member including a plurality of reaction vessels thereon, pre-assigning certain ones of the reaction vessels in the incubation member for only first test types or certain reagent types for all test lots; and pre-assigning other ones of a second subset of reaction vessels in the incubation member for only second test types for all test lots. By ensuring no mixing of potentially interfering test types or reagent types from test lot to test lot, sample and/or reagent carryover is mitigated. Testing apparatus adapted to carry out the methods are provided, as are other aspects.

Abstract: Compounds and compositions are provided that comprise selective b-glucuronidase inhibitors. The compounds and compositions can ameliorate the side effects of chemotherapeutic agents and can improve the efficacy of such agents, including irinotecan and non-steroidal anti-inflammatory drugs.

Abstract: Compounds of Formula I: wherein: one of X and X? is N and the other of X and X? is C, are described, along with compositions containing the same and methods of use thereof in the treatment of cancer.

Abstract: Uses of pyrrolopyrimidines with anti-Mer tyrosine kinase activity as anti-infective agents, immunostimulatory and immunomodulatory agents, anti-cancer agents (including against MerTK?/? tumors and ITD and TKD mutant forms of Acute Myeloid Leukemia (AML)), and as adjunctive agents in combination with chemotherapeutic, radiation or other standard of care for neoplasms.

Abstract: Compounds of Formula I: wherein: one of X and X? is N and the other of X and X? is C, are described, along with compositions containing the same and methods of use thereof in the treatment of cancer.

Abstract: Compounds of Formula I: wherein: one of X and X? is N and the other of X and X? is C, are described, along with compositions containing the same and methods of use thereof in the treatment of cancer.

Abstract: Compound of Formula I: are described, along with pharmaceutically acceptable salts thereof, compositions containing the same, and methods of use thereof in the treatment of cancer.

Abstract: Uses of pyrrolopyrimidines with anti-Mer tyrosine kinase activity as anti-infective agents, immunostimulatory and immunomodulatory agents, anti-cancer agents (including against MerTK?/? tumors and ITD and TKD mutant forms of Acute Myeloid Leukemia (AML)), and as adjunctive agents in combination with chemotherapeutic, radiation or other standard of care for neoplasms.

Abstract: Uses of pyrimidines with anti-Mer tyrosine kinase activity as anti-infective agents, immunostimulatory and immunomodulatory agents, anti-cancer agents (including against MerTK?/? tumors and ITD and TKD mutant forms of Acute Myeloid Leukemia (AML)), and as adjunctive agents in combination with chemotherapeutic, radiation or other standard of care for neoplasms.

Abstract: The present invention includes pyrazolopyrimidine compounds of Formula I that selectively inhibit Mer tyrosine kinase (MerTK) activity and/or Tyro3 tyrosine kinase activity, and use of these pyrazolopyrimidine compounds as anti-cancer agents, immunostimulatory and immunomodulatory agents, anti-platelet agents, anti-infective agents, and as adjunctive agents in combination with chemotherapeutic, radiation or other standard of care for neoplasms.

Abstract: A method of reducing carryover of liquids, such as reagent and/or samples, in analytical or immunoassay testing. The method includes providing an incubation member including a plurality of reaction vessels thereon, pre-assigning certain ones of the reaction vessels in the incubation member for only first test types or certain reagent types for all test lots; and pre-assigning other ones of a second subset of reaction vessels in the incubation member for only second test types for all test lots. By ensuring no mixing of potentially interfering test types or reagent types from test lot to test lot, sample and/or reagent carryover is mitigated. Testing apparatus adapted to carry out the methods are provided, as are other aspects.

Abstract: Compounds of Formula I are described, along with pharmaceutically acceptable salts thereof, compositions containing the same, and methods of use thereof.

Abstract: Pyrazolopyrimidine compounds, methods of use, and processes for making compounds with anti-Mer tyrosine kinase activity comprising Formula I, II, III, IV, or a pharmaceutically acceptable composition, salt, isotopic analog, or prodrug thereof, are provided. The pyrazolopyrimidine compounds described herein have Mer tyrosine kinase (MerTK) inhibitory activity and are useful as anti-infective agents, immunostimulatory and immunomodulatory agents, anti-cancer agents (including against MerTK ?/? tumors and ITD and TKD mutant forms of Acute Myeloid Leukemia (AML)), and as adjunctive agents in combination with chemotherapeutic, radiation or other standard of care for neoplasms.

Abstract: Uses of pyrrolopyrimidines with anti-Mer tyrosine kinase activity as anti-infective agents, immunostimulatory and immunomodulatory agents, anti-cancer agents (including against MerTK?/? tumors and ITD and TKD mutant forms of Acute Myeloid Leukemia (AML)), and as adjunctive agents in combination with chemotherapeutic, radiation or other standard of care for neoplasms.

Abstract: Aspects of the present innovations relate to improved systems that may perform capillary electrophoresis (CE) and CE in conjunction with electrospray ionization (ESI) as an input to a mass spectrometry system (MS). Embodiments may use a current sense circuit at a high voltage output from an MS-ESI power supply in conjunction with additional elements to identify fault conditions associated with leakage current, to confirm the continuity of CE connections, and to provide improved system protection.

Abstract: Compound of Formula I: are described, along with pharmaceutically acceptable salts thereof, compositions containing the same, and methods of use thereof in the treatment of cancer.

Abstract: Compounds of Formula I: wherein: one of X and X? is N and the other of X and X? is C, are described, along with compositions containing the same and methods of use thereof in the treatment of cancer.

Abstract: Compound of Formula (I): are described, along with pharmaceutically acceptable salts thereof, compositions containing the same, and methods of use thereof in the treatment of cancer.